{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:27:31Z","timestamp":1790220451679,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40262-016-0505-1","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T08:39:43Z","timestamp":1483691983000},"page":"1155-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I\/II\/III Studies"],"prefix":"10.1007","volume":"56","author":[{"given":"Nassim","family":"Djebli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Khier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Hurbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"issue":"25","key":"505_CR1","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.jacc.2012.03.011","volume":"59","author":"RA Vogel","year":"2012","unstructured":"Vogel RA. PCSK9 inhibition: the next statin? J Am Coll Cardiol. 2012;59(25):2354\u20135.","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"505_CR2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012;53(12):2515\u201324.","journal-title":"J Lipid Res."},{"issue":"1","key":"505_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","volume":"203","author":"G Lambert","year":"2009","unstructured":"Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203(1):1\u20137.","journal-title":"Atherosclerosis."},{"issue":"3","key":"505_CR4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci. 2003;100(3):928\u201333.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"505_CR5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48(2):646\u201354.","journal-title":"Hepatology."},{"key":"505_CR6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2014.07.004","volume":"145","author":"AD Marais","year":"2015","unstructured":"Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015;145:58\u201366.","journal-title":"Pharmacol Ther."},{"issue":"2","key":"505_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet."},{"issue":"2","key":"505_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161\u20135.","journal-title":"Nat Genet."},{"issue":"12","key":"505_CR9","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med."},{"issue":"3","key":"505_CR10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","volume":"78","author":"IK Kotowski","year":"2006","unstructured":"Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78(3):410\u201322.","journal-title":"Am J Hum Genet."},{"issue":"2","key":"505_CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445\u20138.","journal-title":"Atherosclerosis."},{"issue":"3","key":"505_CR12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514\u201323.","journal-title":"Am J Hum Genet."},{"issue":"16","key":"505_CR13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, Poss J, Bohm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401\u20138.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"505_CR14","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140\u20138.","journal-title":"J Clin Endocrinol Metab."},{"issue":"19","key":"505_CR15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186\u201394.","journal-title":"Eur Heart J."},{"key":"505_CR16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","volume":"14","author":"HM Colhoun","year":"2014","unstructured":"Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014;14:121.","journal-title":"BMC Cardiovasc Disord."},{"key":"505_CR17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"M Farnier","year":"2016","unstructured":"Farnier M, Jones P, Severance R, Averna M, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138\u201346.","journal-title":"Atherosclerosis."},{"issue":"43","key":"505_CR18","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J."},{"issue":"3","key":"505_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","volume":"28","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28(3):281\u20139.","journal-title":"Cardiovasc Drugs Ther."},{"key":"505_CR20","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906\u201315.e13.","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"505_CR21","doi-asserted-by":"crossref","unstructured":"Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554\u201361.","DOI":"10.1016\/j.jacl.2014.09.007"},{"key":"505_CR22","doi-asserted-by":"crossref","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","DOI":"10.1016\/j.jacl.2015.08.006"},{"issue":"10","key":"505_CR23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","volume":"37","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40\u00a0mg) or rosuvastatin (10 or 20\u00a0mg): design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol. 2014;37(10):597\u2013604.","journal-title":"Clin Cardiol."},{"issue":"16","key":"505_CR24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med."},{"issue":"1","key":"505_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fca.14.82","volume":"11","author":"EM Roth","year":"2015","unstructured":"Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75\u00a0mg subcutaneously every 2\u00a0weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27\u201337.","journal-title":"Future Cardiol."},{"key":"505_CR26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","volume":"65","author":"EA Stein","year":"2014","unstructured":"Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65:417\u201331.","journal-title":"Annu Rev Med."},{"issue":"22","key":"505_CR27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","volume":"63","author":"G Lambert","year":"2014","unstructured":"Lambert G, Petrides F, Chatelais M, et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 2014;63(22):2365\u201373.","journal-title":"J Am Coll Cardiol."},{"key":"505_CR28","unstructured":"Praluent\u00ae (alirocumab). Prescribing information (USA). 2015. Available from: \n                        http:\/\/products.sanofi.us\/praluent\/praluent.pdf\n                        \n                    . Accessed 9 Sept 2016."},{"key":"505_CR29","unstructured":"Praluent\u00ae (alirocumab). Summary of product characteristics (EC). 2015. Available from: \n                        http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150923132812\/anx_132812_en.pdf\n                        \n                    . Accessed 9 Sept 2016."},{"issue":"6","key":"505_CR30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","volume":"32","author":"C Lunven","year":"2014","unstructured":"Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297\u2013301.","journal-title":"Cardiovasc Ther."},{"issue":"6","key":"505_CR31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"12","key":"505_CR32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108\u201318.","journal-title":"N Engl J Med."},{"issue":"1","key":"505_CR33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","volume":"15","author":"PP Toth","year":"2016","unstructured":"Toth PP, Hamon SC, Jones SR, et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016;15(1):28.","journal-title":"Lipids Health Dis."},{"key":"505_CR34","doi-asserted-by":"publisher","unstructured":"Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015;4(11). doi:\n                        10.1161\/JAHA.115.002224\n                        \n                     (pii: e002224).","DOI":"10.1161\/JAHA.115.002224"},{"issue":"5","key":"505_CR35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","volume":"114","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u00a0mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711\u20135.","journal-title":"Am J Cardiol."},{"issue":"25","key":"505_CR36","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344\u201353.","journal-title":"J Am Coll Cardiol."},{"issue":"20","key":"505_CR37","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891\u2013900.","journal-title":"N Engl J Med."},{"issue":"9836","key":"505_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29\u201336.","journal-title":"Lancet."},{"issue":"1","key":"505_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55\u201361.","journal-title":"Int J Cardiol."},{"issue":"9","key":"505_CR40","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941\u201352.","journal-title":"J Pharm Sci."},{"issue":"12","key":"505_CR41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","volume":"50","author":"L Sutjandra","year":"2011","unstructured":"Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793\u2013807.","journal-title":"Clin Pharmacokinet."},{"key":"505_CR42","doi-asserted-by":"publisher","unstructured":"Gibbs JP, Doshi S, Kuchimanchi M, et al. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9 (PCSK9). J Clin Pharmacol. 2016. doi:\n                        10.1002\/jcph.840\n                        \n                     (Epub ahead of print).","DOI":"10.1002\/jcph.840"},{"issue":"7","key":"505_CR43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","volume":"11","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;11(7):22.","journal-title":"Lipids Health Dis."},{"issue":"437","key":"505_CR44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","volume":"1","author":"YL Guo","year":"2014","unstructured":"Guo YL, Zhang W, Li JJ. PCSK9 and lipid lowering drugs. Clin Chim Acta. 2014;1(437):66\u201371.","journal-title":"Clin Chim Acta."},{"issue":"25","key":"505_CR45","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/01.CIR.0000018166.84319.55","volume":"105","author":"DH Walter","year":"2002","unstructured":"Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105(25):3017\u201324.","journal-title":"Circulation."},{"issue":"5","key":"505_CR46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mca.0000131572.14521.8a","volume":"15","author":"DH Walter","year":"2004","unstructured":"Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis. 2004;15(5):235\u201342.","journal-title":"Coron Artery Dis."},{"issue":"3","key":"505_CR47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920021503140412212905","volume":"15","author":"S Shi","year":"2014","unstructured":"Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271\u201390.","journal-title":"Curr Drug Metab."},{"issue":"10","key":"505_CR48","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s11095-005-6650-0","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589\u201396.","journal-title":"Pharm Res."},{"issue":"5","key":"505_CR49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573\u201391.","journal-title":"J Pharmacokinet Pharmacodyn."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0505-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T12:29:27Z","timestamp":1505132967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0505-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0505-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]}}}